Drugs / TCN-202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01594437 | May → Dec 2012 | cytomegalovirus infection | Theraclone Sciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCN-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01594437 ↗ |
| Modality | Monoclonal antibody | “Human monoclonal neutralizing antibody” NCT01594437 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT01594437 ↗ |